KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study.

Hans-Christoph Diener, Messoud Ashina, Shannon Ritter, Gabriel Paiva Da Silva Lima, Soeren Rasmussen, Ronald Zielman, Peer Tfelt-Hansen

Cephalalgia 41(11-12) 1262-1267

PMID33939497
PMCIDPMC8504413
DOI10.1177/03331024211010308
发表日期2021-05-03
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: This post-hoc analysis was conducted to evaluate the effect of erenumab on monthly migraine days, monthly migraine attacks, and attack duration in patients with episodic migraine to investigate whether erenumab actually prevents the occurrence of migraine attacks and/or shortens them. METHODS: We conducted a post-hoc analysis of the data from the STRIVE study, in 955 patients with episodic migraine. Relative changes from baseline to mean over months 4, 5 and 6 of the double-blind treatment phase in monthly migraine days, monthly migraine attacks and mean migraine attack duration were assessed. RESULTS: Erenumab reduced monthly migraine days and monthly migraine attacks compared with placebo in a similar way. Erenumab had only a minor impact on shortening the duration of migraine attacks. CONCLUSION: These post-hoc analyses demonstrate that the decrease in monthly migraine days by erenumab is mainly driven by a reduction in the frequency of monthly migraine attacks and to a much lesser extent by shortening the duration of migraine attacks.Trial registration: This study is registered at ClinicalTrials.gov (NCT02456740).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。